MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab, an investigational Nanobody therapy for inflammatory diseases. Its lead programs target conditions such as hidradenitis suppurativa and psoriatic arthritis, with additional work in related dermatology and rheumatology indications. The company focuses on patients with substantial unmet need rather than marketed commercial products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -55.2 | — |
| Q3 2025 | 0 | — | -69.7 | — |
| Q4 2025 | 0 | — | -62.4 | — |
| Q1 2026 | 0 | — | -69.7 | — |
| Q2 2026 | 0 | — | -61.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Kura Oncology, Inc. (KURA), Playtika Holding Corp. (PLTK), SpyGlass Pharma, Inc. (SGP), Corvus Pharmaceuticals, Inc. (CRVS), World Acceptance Corporation (WRLD), Ardelyx, Inc. (ARDX)